Since 2013, Dr. Brantley has developed expertise in clinical and nonclinical pharmacology, pharmacokinetics, pharmacometrics and scientific writing. Dr. Brantley’s focus is mostly in early phase oncology and antiviral programs. Dr. Brantley has worked on approximately 11 approved drugs, 3 NDAs, 5 INDs, 90+ PK and population PK analyses.
Education